Trichomonas vaginalis Antibody (8.F.284): sc-58064

Trichomonas vaginalis Antibody (8.F.284) is a mouse monoclonal IgG1 antibody that detects the Trichomonas vaginalis protein of Trichomonas vaginalis origin by immunofluorescence (IF) and enzyme-linked immunosorbent assay (ELISA). Anti-Trichomonas vaginalis antibody (8.F.284) is available as the non-conjugated format. Trichomonas vaginalis is an anaerobic parasite responsible for trichomoniasis, a prevalent infection of the genitourinary tract and the most common pathogenic protozoan infection in humans. This organism is notable for its unique hydrogenosome organelles, which play a crucial role in energy metabolism by converting pyruvate and malate into hydrogen and acetate, thus allowing the parasite to thrive in anaerobic conditions. The presence of hydrogenosomes is significant because they enable Trichomonas vaginalis to maintain its energy requirements through glycolysis, compensating for the absence of mitochondria and oxidative phosphorylation. Additionally, Trichomonas vaginalis exhibits remarkable resilience, capable of surviving for up to 24 hours in various environments, including urine, semen, and water samples, which underscores its potential for transmission and persistence in human populations. The ability of Trichomonas vaginalis to capture nutrients through phagocytosis further enhances its survival and pathogenicity, making it an important target for research and diagnostic applications.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Trichomonas vaginalis Antibody (8.F.284) References:

1. Cysteine biosynthesis in Trichomonas vaginalis involves cysteine synthase utilizing O-phosphoserine.  |  Westrop, GD., et al. 2006. J Biol Chem. 281: 25062-75. PMID: 16735516
2. Association of bacterial vaginosis, trichomonas vaginalis, and vaginal acidity with outcome of pregnancy.  |  Azargoon, A. and Darvishzadeh, S. 2006. Arch Iran Med. 9: 213-7. PMID: 16859053
3. [Detection of Mycoplasma hominis in Trichomonas vaginalis by PCR].  |  Fang, SL., et al. 2006. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 24: 144-5. PMID: 16862916
4. Trichomonas vaginalis initiator binding protein (IBP39) and RNA polymerase II large subunit carboxy terminal domain interaction.  |  Lau, AO., et al. 2006. Mol Biochem Parasitol. 150: 56-62. PMID: 16879883
5. Trichomonas vaginalis promotes apoptosis of human neutrophils by activating caspase-3 and reducing Mcl-1 expression.  |  Kang, JH., et al. 2006. Parasite Immunol. 28: 439-46. PMID: 16916367
6. Methods for detection of Trichomonas vaginalis in the male partners of infected women: implications for control of trichomoniasis.  |  Hobbs, MM., et al. 2006. J Clin Microbiol. 44: 3994-9. PMID: 16971646
7. Identification and biochemical characterization of serine hydroxymethyl transferase in the hydrogenosome of Trichomonas vaginalis.  |  Mukherjee, M., et al. 2006. Eukaryot Cell. 5: 2072-8. PMID: 16980404
8. Trichomonas vaginalis detection using real-time TaqMan PCR.  |  Schirm, J., et al. 2007. J Microbiol Methods. 68: 243-7. PMID: 17005275
9. Trichomonas vaginalis pathobiology new insights from the genome sequence.  |  Hirt, RP., et al. 2011. Adv Parasitol. 77: 87-140. PMID: 22137583
10. Strategies for Prevention and Treatment of Trichomonas vaginalis Infections.  |  Bouchemal, K., et al. 2017. Clin Microbiol Rev. 30: 811-825. PMID: 28539504
11. Polyamine Transport and Synthesis in Trichomonas vaginalis: Potential Therapeutic Targets.  |  Alvarez-Sanchez, ME., et al. 2017. Curr Pharm Des. 23: 3359-3366. PMID: 28671057
12. Two novel serum-free media for the culture of Trichomonas vaginalis.  |  Limoncu, ME., et al. 2007. Parasitol Res. 100: 599-602. PMID: 16947014